Advertisement
The U.S. Food and Drug Administration recently announced the approval of Daurismo (glasdegib) tablets for use in combination with a low dose of the chemotherapy cytarabine to treat newly diagnosed acute myeloid leukemia. The treatment is indicated for patients aged 75 years or older who have comorbidities that may prevent the use of intensive chemotherapy.

FDA Approves New Treatment for Acute Myeloid Leukemia

0
Randomized clinical trial showed significant improvement in overall survival with Daurismo
For patients with prostate cancer

ADT May Up Risk for Heart Failure in Prostate Cancer Patients

0
Heart failure risk higher for androgen deprivation therapy users in propensity score-matched analysis
For children with acute gastroenteritis

Probiotics Show No Benefits for Pediatric Acute Gastroenteritis

0
No benefits seen with Lactobacillus rhamnosus GG or L. rhamnosus R0011 and L. helveticus R0052
For patients with primary progressive multiple sclerosis

Ocrelizumab May Help Preserve Hand, Arm Function in PPMS

0
Ocrelizumab reduces risk for more severe progression
From 2018 to 2030

Insulin Needed for T2DM Tx Set to Increase >20 Percent by 2030

0
Using higher HbA1c target in over-75s could increase disability-adjusted life-years by 44.2 percent
The U.S. Preventive Services Task Force (USPSTF) recommends HIV screening for individuals aged 15 to 65 years

USPSTF Suggests Universal HIV Screening, PrEP for High-Risk Patients

0
Screening recommended for those ages 15 to 65 years, including pregnant women
Antibiotic use in children <24 months of age is associated with a slightly higher body weight at 5 years of age

Early Antibiotic Use May Be Tied to Higher Childhood Body Weight

0
Antibiotics before age 2 associated with very small increase in body weight at 5 years of age
Millions of workers gained insurance coverage under the Affordable Care Act without adverse effects on labor markets

ACA Coverage Substantial, but Did Not Impact Labor Markets

0
Coverage gains did not negatively impact employment levels, hours worked, earnings
During a median follow-up of 6.8 years

Few Mandatory Pediatric Postmarketing Studies Completed

0
33.8 percent of mandatory pediatric postmarketing studies completed during 6.8 years of follow-up
A new scoring system that accounts for "not relevant" responses on the Dermatology Life Quality Index for patients with psoriasis is valid for avoiding bias and can improve access to biologics

Novel Scoring System Can Up Access to Biologics in Psoriasis

0
DLQI-R allows more patients to achieve threshold for becoming candidates for biologic treatment